To add to your thoughts on these natural substances and
To add to your thoughts on these natural substances and their ability to serve medicinal purposes, many of these powders/oils/etc do have evidence of efficacy but it's usually in some lab or poorly designed "study" and they're often not ultimately doing a damn thing when we take them. Besides maybe a meager placebo effect.
Take Saw Palmetto as an example. Constantly touted as an effective treatment for BPH (enlarged prostate and the symptoms that accompany it). I once spoke to a very well respected hospital's chief of naturopathy about it. He'd looked into it, along with many other things with optimism and vigor because that was job to do so. Spoiler alert, he said it did nothing.
From WebMD:
Saw palmetto: This is a short tree that grows in North America. Some small studies have shown a benefit. However, several large studies do not show that saw palmetto reduces the size of the prostate or eases urinary symptoms.
The way he explained it was that for the supposed effects to show up you'd have to take a dose that's unreasonable to both produce and consume, and even then it's arguable whether or not it would do anything.
It's like all of the covid "cures" and "promising treatments" coming out of the woodwork. Jlang could set up a petri dish in his van down by an undisclosed river and subject it to readings of his past posts, and the virus would probably die in vitro. Or kill itself* to end the misery.
*Oh shit! I think I may have inadvertently created a cure for Covid you guys!
Many things can work in a lab or a mouse and ultimately have zero effect in humans. Natural remedies are our best example of that.
Now that I've pointed that out I'll admit that some things can and do work, they're just the exception. Hell, I used to sell a drug called Condylox Gel that killed wart tissue. It was specifically tested and approved based on trials for genital warts, but like those who contract genital warts it was taking all comers (heyooo) and would work on regular old warts too. It killed the tissue. Nobody knew exactly why, but it was derived from a flower (or plant, I can't be bothered to look it up right now) and that's some powerful flower assassin type shit. They could make a hell of a CSI episode around that flower. #FlowerPower #TissueDeath
At any rate, there are plenty of things that will likely work just as much as natural cures and I've listed a couple below.
- Snorting Pixy Stix
- Rubbing yourself in Respert's preferred steak seasoning, Chicago Steak by - - - Weber
- Watching JLang lose to Ohm and CTMedic in a science battle
- Putting people on ignore that deserve it
- Flaming Dr. Peppers
#TechnicalAnalysis
12
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Do Shoppers Believe in Black Friday Anymore? You'd think by now, retailers would have cracked the code on building trust with their customers. But guess what? A fresh survey from Boston Consulting Group reveals only 54% of consumers buy the whole Black Friday discount story. That's barely more than flipping a coin. Promotion Fatigue: The Trust Buster Funny thing,...
Continue Reading
Biotech Giants CStone and Kimia Unite Forces In the heart of China's biotechnology scene, the latest collaboration news to hit the wires is CStone Pharmaceuticals shaking hands with Kimia Therapeutics. Now, don't go tossing this aside as another run-of-the-mill partnership announcement. CStone's HKEX: 2616 ticker has got its eyes locked on an ambitious dance with Kimia,...
Continue Reading
Samsung Biologics Achieves a Low-Risk Triumph You gotta hand it to Samsung Biologics for hitting a 'Negligible Risk' rating. Their latest score? A cool 9.0. That’s like walking into the pharmaceuticals room and getting a standing ovation. It's no small feat—climbing up from a 'Low Risk' rating to the top tier in Morningstar Sustainalytics' playbook. For us spectating...
Continue Reading
Diving into Emergency General Surgery Verification How often do you hear a hospital accreditation making a real difference? The latest report in JAMA Surgery suggests it’s more than just a plaque on the wall for some. We're talking about the American College of Surgeons (ACS) Emergency General Surgery Verification program, which links directly to better patient...
Continue Reading
Stellus Capital's Upcoming Financial Reveal: Stakes and Details November's not just bringing the cold breezes, folks; it's also ushering in the much-anticipated financial digits of Stellus Capital Investment Corporation's third quarter of 2026. Mark your calendars for November 9, after the stock market wraps up, when Stellus will drop its operational performance stats for...
Continue Reading
Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...
Continue Reading
Movie Magic on the Menu When was the last time a bucket of fried chicken sent such ripple effects through pop culture? KFC's decision to sling Doctor Doom-inspired dishes across 100 countries smells like genius business mixed with a dash of the absurd. Just imagine: an empire of battered birds aligning with Marvel's latest cinematic heavy hitter, "Avengers: Doomsday." Now...
Continue Reading
Shaky Ground Beneath AppLovin's Feet Ah, the sweet smell of litigation in the tech space—it’s like déjà vu for seasoned market folks. Here we have AppLovin, nestled comfortably in San Francisco, now eying a saucy class-action lawsuit. We're looking at shareholders taking a firm stance against some arguably misleading claims. We're talking big deals with allegations...
Continue Reading
Breaking Ground in Healthcare Tech Ah, what’s cooking in Singapore? On a day like today, when the tech giants Singtel and Ericsson get chummy with National University Health System (NUHS), we're looking at the kind of healthcare advancements that read like science fiction. They’ve signed an MOU to launch the National University XG AI Centre (NXAC) – a mouthful,...
Continue Reading
Here’s how it is: choosing a lakefront home in Steuben County, Indiana, ain't just about picking a place with a killer view. It’s like buying a lifestyle package and you’d better know what you’re getting. An article by Tony Isa, the go-to real estate guru in these parts, puts the spotlight on Lake James and Clear Lake—but what matters is how each might wrangle...
Continue Reading
Top 5 Most Recently Viewed Articles
Recent Insider Trading at Teva Pharmaceutical Industries A notable insider transaction occurred recently, with Amir Weiss, the Chief Accounting Officer at Teva Pharmaceutical Industries Ltd (NYSE: TEVA), unloading shares worth $300,564 as reported by a recent SEC filing. Details of the Transaction According to the Form 4 filing submitted to the U.S. Securities and...
Continue Reading
Transforming Mobility with Robotaxi Services TIER IV, renowned for developing the first open-source software for autonomous driving, has teamed up with mobility startup Newmo to revolutionize transportation services. This partnership marks a significant step toward the commercialization of robotaxi services, offering solutions tailored for local communities. Your Solution...
Continue Reading
Investors Urged to Take Action After Stock Price Drop Recent developments surrounding Wolfspeed, Inc. have raised significant concerns among investors, especially following the staggering drop in the company's stock price. Those who invested in Wolfspeed, often identified by its ticker WOLF, may now find themselves questioning their portfolio decisions. Amidst this...
Continue Reading
Team Falcons' Incredible Journey to Victory The culmination of the Esports World Cup 2025 showcased an exhilarating journey for Team Falcons, who emerged as the dominant force in this prestigious multi-title esports tournament. Over seven weeks, the tournament attracted a staggering 750 million viewers worldwide and recorded 350 million hours of online watch time. These...
Continue Reading
GENFIT Files 2024 Universal Registration Document Lille, France - GENFIT (Nasdaq and Euronext: GNFT), a pioneering biopharmaceutical firm dedicated to the welfare of patients suffering from rare and life-threatening liver conditions, has achieved a significant milestone by filing its 2024 Universal Registration Document alongside its Annual Report on Form 20-F with...
Continue Reading